Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ACN: 080 699 065) covers the month of December 2006. The registrant is a foreign private issuer based in South Melbourne, Australia, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934. The filing discloses changes in directors' interests in securities effective December 15, 2006.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is exclusively a disclosure of changes in directors' share and option holdings.
Material Changes Versus Prior Period
On December 15, 2006, five directors acquired additional options under the Prana Biotechnology Limited Employee Share & Option Incentive Plan, approved at the Annual General Meeting on November 30, 2006. No shares were acquired or disposed of during this period.
- Geoffrey Kempler: Acquired 1,000,000 options. Total options held increased from 1,000,000 to 2,000,000.
- Colin Masters: Acquired 1,000,000 options. Total options held increased from 1,000,000 to 2,000,000.
- George Mihaly: Acquired 300,000 options. Total options held increased from 300,000 to 600,000.
- Peter Marks: Acquired 300,000 options. Total options held increased from 300,000 to 600,000.
- Brian Meltzer: Acquired 300,000 options (indirect interest). Total options held increased from 300,000 to 600,000.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the significant increase in option holdings for all listed directors, which was executed as a non-cash issuance under the company's incentive plan.
Important Facts for Investor Verification
- Verify the terms and vesting schedules of the 2,900,000 total options granted to directors on December 15, 2006.
- Confirm the impact of these grants on the company's total outstanding option pool and potential dilution.
- Review the November 30, 2006 Annual General Meeting resolutions (Resolutions 3, 4, 5, 6, and 7) to understand the specific conditions attached to these grants.
- Note that the filing references "Altery Therapeutics Ltd" in metadata but the document text explicitly identifies the registrant as "Prana Biotechnology Limited"; verify the current corporate name and ticker symbol.